Industry-Sponsored Symposium - Microbiome Therapeutics and Recurrent Clostridioides difficile: Where Do We Go From Here?

Paul Feuerstadt, MD, FACG, Jessica R. Allegretti, MD, MPH, FACG, Krishna Rao, MD, MS

Supported by an independent educational grant from Seres Therapeutics, Inc. & Aimmune Therapeutics.

Clostridioides difficile can cause a serious infection of the lower intestine, resulting in significant morbidity and sometimes death. The primary risk factor for C difficile infection (CDI) is exposure to broad-spectrum antibiotics, which disrupt the normal composition and function of the gut microbiome. Antibiotics for CDI treatment do not kill bacterial spores, and recurrence is common. Restoring a healthy gut microbiome is therefore often critical for achieving a durable clinical response. In this live CME event, three clinician experts will review treatments for recurrent CDI that target the gut microbiome, including fecal microbiota transplantation and emerging live biopharmaceutical products. Faculty will discuss these therapies in the context of interactive patient cases; audience participation will be encouraged through a live Q&A.

A recording of this presentation will be available to all ACG 2022 attendees on the ACG Conference Platform after the live session through March 31, 2023.

Open to all ACG 2022 attendees, industry-sponsored symposia provide additional educational opportunities. These programs are independent of the ACG 2022 Annual Scientific Meeting and Postgraduate Course programs. ACG is not the continuing medical education provider of these programs. For more information, see the company sponsor.